Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 242 Carboplatin 137 Nivolumab 132 Gemcitabine 127 Paclitaxel 116 Cisplatin 105 Cyclophosphamide 97 Bevacizumab 93 Dexamethasone 78 Injections 75 Pemetrexed 71 Docetaxel 71 Fluorouracil 68 Capecitabine 65 Rituximab 61 Cetuximab 61 atezolizumab 59 130-nm albumin-bound paclitaxel 59 Oxaliplatin 58 Leucovorin 57 Ipilimumab 54 fludarabine 50 Lenalidomide 47 Azacitidine 40 Irinotecan 39 venetoclax 38 Fulvestrant 38 Albumin-Bound Paclitaxel 36 Prednisone 35 Trastuzumab 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × INDUSTRY × Ice × Clear all

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡